Advanced search
Publication Cover
Leukemia & Lymphoma Volume 54, 2013 - Issue 3
Submit an article Journal homepage
261
Views
10
CrossRef citations to date
0
Altmetric
Research Article

Bortezomib may be safely combined with Y-90-ibritumomab tiuxetan in patients with relapsed/refractory follicular non-Hodgkin lymphoma: a phase I trial of combined induction therapy and bortezomib consolidation

Rupali RoyDepartment of Medicine, Robert H. Lurie Comprehensive Cancer CenterCorrespondence[email protected]
,
Andrew M. EvensDepartment of Medicine, University of Massachusetts Memorial Cancer Center, The University of Massachusetts Medical School, Worcester, MA, USA
,
David PattonDepartment of Medicine, Robert H. Lurie Comprehensive Cancer Center
,
Lillia GallotDepartment of Medicine, Robert H. Lurie Comprehensive Cancer Center
,
Annette LarsonDepartment of Medicine, University of Massachusetts Memorial Cancer Center, The University of Massachusetts Medical School, Worcester, MA, USA
,
Alfred RademakerDepartment of Preventative Medicine
,
Jeffrey CilleyDepartment of Medicine, Robert H. Lurie Comprehensive Cancer Center
,
Stewart SpiesDepartment of Radiology
,
Daina VariakojisDepartment of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
,
Leo I. GordonDepartment of Medicine, Robert H. Lurie Comprehensive Cancer Center
&
Jane N. WinterDepartment of Medicine, Robert H. Lurie Comprehensive Cancer Center
 show all
Pages 497-502 | Received 29 Mar 2012, Accepted 13 Jul 2012, Published online: 11 Sep 2012

Citations (10)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Mahsa Eskian, MirHojjat Khorasanizadeh, Pier Luigi Zinzani, Tim M. Illidge & Nima Rezaei. (2019) Novel Methods to Improve the Efficiency of Radioimmunotherapy for Non-Hodgkin Lymphoma. International Reviews of Immunology 38:2, pages 79-91.
Read now
Florine Obrist, Gwenola Manic, Guido Kroemer, Ilio Vitale & Lorenzo Galluzzi. (2015) Trial Watch: Proteasomal inhibitors for anticancer therapy. Molecular & Cellular Oncology 2:2.
Read now
Rebecca L. Elstrom, Jia Ruan, Paul J. Christos, Peter Martin, Daniel Lebovic, Joseph Osborne, Stanley Goldsmith, June Greenberg, Richard R. Furman, Anca Avram, Ryan Putman, Erica Chapman, Madhu Mazumdar, Kent Griffith, Morton Coleman, John P. Leonard & Mark S. Kaminski. (2015) Phase 1 study of radiosensitization using bortezomib in patients with relapsed non-Hodgkin lymphoma receiving radioimmunotherapy with 131I-tositumomab. Leukemia & Lymphoma 56:2, pages 342-346.
Read now
Norma Bloy, Jonathan Pol, Gwenola Manic, Ilio Vitale, Alexander Eggermont, Jérôme Galon, Eric Tartour, Laurence Zitvogel, Guido Kroemer & Lorenzo Galluzzi. (2014) Trial Watch: Radioimmunotherapy for oncological indications. OncoImmunology 3:9.
Read now

Articles from other publishers (6)

Aurélie Rondon, Jacques Rouanet & Françoise Degoul. (2021) Radioimmunotherapy in Oncology: Overview of the Last Decade Clinical Trials. Cancers 13:21, pages 5570.
Crossref
Grerk Sutamtewagul & Brian K. Link. (2019) Novel treatment approaches and future perspectives in follicular lymphoma. Therapeutic Advances in Hematology 10, pages 204062071882051.
Crossref
Koichiro Abe. 2018. Resistance to Ibritumomab in Lymphoma. Resistance to Ibritumomab in Lymphoma 33 57 .
Ping-Pin Zheng, Jin Li & Johan M Kros. (2018) Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research-practice gaps, challenges, and insights. Medicinal Research Reviews 38:1, pages 325-376.
Crossref
Huizi Keiko LiYukie MorokoshiKazuhiro DainoTakako FurukawaTadashi KamadaTsuneo SagaSumitaka Hasegawa. (2015) Transcriptomic Signatures of Auger Electron Radioimmunotherapy Using Nuclear Targeting 111 In-Trastuzumab for Potential Combination Therapies . Cancer Biotherapy and Radiopharmaceuticals 30:8, pages 349-358.
Crossref
Colin Rae, Mathias Tesson, John W Babich, Marie Boyd & Robert J Mairs. (2013) Radiosensitization of noradrenaline transporter-expressing tumour cells by proteasome inhibitors and the role of reactive oxygen species. EJNMMI Research 3:1.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.